212 related articles for article (PubMed ID: 11994126)
1. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat.
Calvo P; Gouritin B; Villarroya H; Eclancher F; Giannavola C; Klein C; Andreux JP; Couvreur P
Eur J Neurosci; 2002 Apr; 15(8):1317-26. PubMed ID: 11994126
[TBL] [Abstract][Full Text] [Related]
2. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo P; Gouritin B; Chacun H; Desmaële D; D'Angelo J; Noel JP; Georgin D; Fattal E; Andreux JP; Couvreur P
Pharm Res; 2001 Aug; 18(8):1157-66. PubMed ID: 11587488
[TBL] [Abstract][Full Text] [Related]
3. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier.
Andrieux K; Couvreur P
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(5):463-74. PubMed ID: 20049811
[TBL] [Abstract][Full Text] [Related]
4. Early detection of liposome brain localization in rat experimental allergic encephalomyelitis.
Rousseau V; Denizot B; Le Jeune JJ; Jallet P
Exp Brain Res; 1999 Apr; 125(3):255-64. PubMed ID: 10229016
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
[TBL] [Abstract][Full Text] [Related]
6. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases.
Calvo P; Gouritin B; Brigger I; Lasmezas C; Deslys J; Williams A; Andreux JP; Dormont D; Couvreur P
J Neurosci Methods; 2001 Oct; 111(2):151-5. PubMed ID: 11595281
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 as a CNS therapeutic: the obstacle of the blood-brain/blood-spinal cord barrier.
Kastin AJ; Akerstrom V; Pan W
Brain Res Mol Brain Res; 2003 Jun; 114(2):168-71. PubMed ID: 12829328
[TBL] [Abstract][Full Text] [Related]
8. Distribution of albumin nanoparticles in animals induced with the experimental allergic encephalomyelitis.
Merodio M; Irache JM; Eclancher F; Mirshahi M; Villarroya H
J Drug Target; 2000; 8(5):289-303. PubMed ID: 11328657
[TBL] [Abstract][Full Text] [Related]
9. Blood-brain barrier changes and cell invasion differ between therapeutic immune clearance of neurotrophic virus and CNS autoimmunity.
Fabis MJ; Phares TW; Kean RB; Koprowski H; Hooper DC
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15511-6. PubMed ID: 18829442
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the timing of acute blood-brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis.
Tonra JR; Reiseter BS; Kolbeck R; Nagashima K; Robertson R; Keyt B; Lindsay RM
J Comp Neurol; 2001 Jan; 430(1):131-44. PubMed ID: 11135250
[TBL] [Abstract][Full Text] [Related]
11. Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease.
Koh CS; Gausas J; Paterson PY
J Neuroimmunol; 1993 Sep; 47(2):141-5. PubMed ID: 8370766
[TBL] [Abstract][Full Text] [Related]
12. Applications of nanotechnology in drug delivery to the central nervous system.
Saeedi M; Eslamifar M; Khezri K; Dizaj SM
Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a radiolabelled peripheral benzodiazepine receptor ligand in the central nervous system inflammation of experimental autoimmune encephalomyelitis: a possible probe for imaging multiple sclerosis.
Mattner F; Katsifis A; Staykova M; Ballantyne P; Willenborg DO
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):557-63. PubMed ID: 15875181
[TBL] [Abstract][Full Text] [Related]
14. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration.
Pepinsky RB; Shao Z; Ji B; Wang Q; Meng G; Walus L; Lee X; Hu Y; Graff C; Garber E; Meier W; Mi S
J Pharmacol Exp Ther; 2011 Nov; 339(2):519-29. PubMed ID: 21807883
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier in chronic relapsing experimental allergic encephalomyelitis: a correlative study between cerebrospinal fluid protein concentrations and tracer leakage in the central nervous system.
Kitz K; Lassmann H; Karcher D; Lowenthal A
Acta Neuropathol; 1984; 63(1):41-50. PubMed ID: 6730912
[TBL] [Abstract][Full Text] [Related]
16. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
[TBL] [Abstract][Full Text] [Related]
17. Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice.
Butter C; Baker D; O'Neill JK; Turk JL
J Neurol Sci; 1991 Jul; 104(1):9-12. PubMed ID: 1919601
[TBL] [Abstract][Full Text] [Related]
18. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles.
Garcia-Garcia E; Gil S; Andrieux K; Desmaële D; Nicolas V; Taran F; Georgin D; Andreux JP; Roux F; Couvreur P
Cell Mol Life Sci; 2005 Jun; 62(12):1400-8. PubMed ID: 15905957
[TBL] [Abstract][Full Text] [Related]
19. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme.
Wolburg H; Wolburg-Buchholz K; Kraus J; Rascher-Eggstein G; Liebner S; Hamm S; Duffner F; Grote EH; Risau W; Engelhardt B
Acta Neuropathol; 2003 Jun; 105(6):586-92. PubMed ID: 12734665
[TBL] [Abstract][Full Text] [Related]
20. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting.
Brigger I; Morizet J; Aubert G; Chacun H; Terrier-Lacombe MJ; Couvreur P; Vassal G
J Pharmacol Exp Ther; 2002 Dec; 303(3):928-36. PubMed ID: 12438511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
